Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/62158
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3505]
Metadata
Show full item record
THE EFFECT OF TB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE FOR PEOPLE WITH ADVANCED HIV
Author
Affilliation
Kenya Medical Research Institute. HIV-Research Branch. Kisumu, Kenya.
Harvard T. H. Chan School of Public Health. Boston, MA, USA.
Kenya Medical Research Institute. HIV-Research Branch. Kisumu, Kenya.
Harvard T. H. Chan School of Public Health. Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
University of North Carolina School of Medicine. Chapel Hill, NC, USA / University of North Carolina Project. Lilongwe, Malawi.
Perlman School of Medicine at the University of Pennsylvania. PA, USA.
Johns Hopkins Project. Blantyre, Malawi.
Johns Hopkins University School of Medicine. Baltimore, MD, USA.
Johns Hopkins Project. Blantyre, Malawi.
Joint Clinical Research Centre Clinical Research Site. Kampala, Uganda.
Byramjee Jeejeebhoy Government Medical College Clinical Trials Unit. Pune, India.
YRGCARE Medical Centre. Chennai Antiviral Research and Treatment Clinical Research Site. Chennai, India.
Centers for Disease Control and Prevention. Atlanta, GA, USA.
Harvard T. H. Chan School of Public Health. Boston, MA, USA.
Kenya Medical Research Institute. HIV-Research Branch. Kisumu, Kenya.
Harvard T. H. Chan School of Public Health. Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
University of North Carolina School of Medicine. Chapel Hill, NC, USA / University of North Carolina Project. Lilongwe, Malawi.
Perlman School of Medicine at the University of Pennsylvania. PA, USA.
Johns Hopkins Project. Blantyre, Malawi.
Johns Hopkins University School of Medicine. Baltimore, MD, USA.
Johns Hopkins Project. Blantyre, Malawi.
Joint Clinical Research Centre Clinical Research Site. Kampala, Uganda.
Byramjee Jeejeebhoy Government Medical College Clinical Trials Unit. Pune, India.
YRGCARE Medical Centre. Chennai Antiviral Research and Treatment Clinical Research Site. Chennai, India.
Centers for Disease Control and Prevention. Atlanta, GA, USA.
Abstract
Introduction: We evaluated the impact of empirical tuberculosis (TB) therapy versus isoniazid preventive therapy (IPT) in addition to antiretroviral therapy (ART) among people living with HIV (PLHIV) on health-related quality of life (HRQoL), assessed changes over time, and examined associations between sociodemographic and clinical factors. Methods: Participants >13 years were enrolled from outpatient clinics in 10 countries. HRQoL was assessed at weeks 0, 8, 24 and 96 with questions about daily activity, hospital or emergency room visits, and general health status. We used logistic regression to examine HRQoL by arm and association with sociodemographic and clinical factors. Results: Among 850 participants (424 empiric arm, 426 IPT arm), HRQoL improved over time with no difference between arms. At baseline and week 24, participants with WHO stage 3 or 4 events, or who had grade 3 or 4 signs/ symptoms, were significantly more likely to report poor HRQoL using the composite of four HRQoL measures. Conclusions: HRQoL improved substantially in both arms during the study period. These findings show that ART, TB screening, and IPT can not only reduce mortality, but also can improve HRQoL in PLHIV with advanced disease.
Share